

Pathological Role of HDAC8: Cancer and Beyond

Ji Yoon Kim [†] , Hayoung Cho [†], Jung Yoo, Go Woon Kim, Yu Hyun Jeon, Sang Wu Lee and So Hee Kwon ^{*} 

College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Korea

^{*} Correspondence: soheekwon@yonsei.ac.kr; Tel.: +82-32-749-4513[†] These authors contributed equally to this work.

Abstract: Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and overexpression of HDAC8 give rise to diseases. HDAC8 is especially involved in various aspects of cancer progression, such as cancer cell proliferation, metastasis, immune evasion, and drug resistance. HDAC8 is also associated with the development of non-cancer diseases such as Cornelia de Lange Syndrome (CdLS), infectious diseases, cardiovascular diseases, pulmonary diseases, and myopathy. Therefore, HDAC8 is an attractive therapeutic target and various HDAC8 selective inhibitors (HDAC8is) have been developed. Here, we address the pathological function of HDAC8 in cancer and other diseases, as well as illustrate several HDAC8is that have shown anti-cancer effects.

Keywords: HDAC8; HDAC8 selective inhibitors; epigenetics; cancer



Citation: Kim, J.Y.; Cho, H.; Yoo, J.; Kim, G.W.; Jeon, Y.H.; Lee, S.W.; Kwon, S.H. Pathological Role of HDAC8: Cancer and Beyond. *Cells* **2022**, *11*, 3161. <https://doi.org/10.3390/cells11193161>

Academic Editors: Yinghui Li and Kamalakshi Deka

Received: 2 September 2022

Accepted: 5 October 2022

Published: 9 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Epigenetics is the study of changes in gene expression without changes in DNA sequences [1]. The dynamic epigenetic status of chromatin regulates cell development, differentiation, growth, cell cycle, and aging, which collectively affect human health and diseases. Given that the accumulation of epigenetic alterations is heritable and drives the malignant transformation of cells, a better understanding of epigenetic mechanisms may expand potential treatment options for various diseases. Epigenetic treatments are particularly promising because epigenetic alterations are reversible by chemical drugs or gene therapy, reverting the pathological phenotypes to normal [2].

Post-translational modifications (PTMs) of histones include acetylation, phosphorylation, methylation, ubiquitination, and SUMOylation. Among these modifications, histone acetylation notably modifies the chromosomal structure and regulates gene expression [3,4]. Histone deacetylase (HDAC) removes the acetyl group from lysine residues of histones. This results in the formation of condensed heterochromatin and principally suppresses gene expression [5]. HDACs also target non-histone proteins and regulate critical biochemical functions such as protein stability, mRNA stability, and enzyme activity. Regular functions of HDACs are required for hematopoiesis and the development of the heart, muscle, and skeleton. Deregulation of HDACs may cause neurodegenerative diseases, metabolic disorders, and inflammation [6–8]. HDAC overexpression is commonly detected in advanced stages of cancer and drives poor outcomes in patients, suggesting that HDACs are involved in multiple stages of cancer [9].

Mammalian HDACs consist of 18 isoforms that are divided into four classes based on their sequence similarity to yeast factors and cofactor dependency [7]. Class I (HDAC1, HDAC2, HDAC3, HDAC8), class IIa (HDAC4, HDAC5, HDAC7, HDAC9), class IIb (HDAC6, HDAC10), and class IV (HDAC11) belong to the classical family that requires Zn²⁺ for the enzyme activity. Class III (SIRT1–7) HDACs are classified as silent information regulator 2 (Sir2)-related proteins (sirtuin) family and require NAD⁺ as a cofactor [10].

Since the identification of HDAC8 as the latest member of class I HDAC in 2000, it has been both structurally and functionally well-studied through advanced cellular experiments [11–13]. HDAC8 performs critical roles in human gene transcription and pathophysiology by targeting core histones as well as non-histone substrates, such as p53 and structural maintenance of chromosomes 3 (SMC3) [14–16]. This review will explore various functions of HDAC8 and its importance in diseases. In particular, we summarize recent studies of HDAC8 in cancer development and suggest HDAC8 as a potential therapeutic target in human cancers.

2. Subcellular Localization and Structure of HDAC8

HDAC8 is a sex-linked gene that is located in the chromosomal position Xq13.1 [13]. The complete sequencing of 377 amino acid residues and phylogenetic analysis of HDAC8 categorized the enzyme to class I HDAC. HDAC8 has over 30% amino acid identity with other class I HDACs, including the nine conserved blocks that serve the catalytic function of deacetylase, but have a shorter C-terminal sequence [11,13]. Originally, HDAC8 was characterized as a nuclear protein [12]. However, various studies have identified the nuclear and cytoplasmic distribution of HDAC8 [17–19] and predominant cytoplasmic localization in smooth muscle, brain, and melanoma cells [20–23]. Li et al. demonstrated that AMP-activated protein kinase (AMPK) phosphorylates HDAC8 and mediates its translocation to the cytoplasm from the nucleus, suggesting that phosphorylation may be used to direct subcellular localization of HDAC8 depending on its function and cellular condition [24].

HDAC8 is the first human HDAC to have its three-dimensional structure experimentally determined by X-ray crystallography (Figure 1) [15]. Structurally, HDAC8 is a head-to-head dimer of two essentially identical molecules. Each molecule possesses one zinc-binding site that promotes catalytic activity and two potassium-binding sites that enhance structural stability. The metal binding sites are interconnected and determine the enzyme activity of HDAC8 [25]. The active site of HDAC8 comprises a hydrophobic tunnel that leads to the catalytic machinery [15]. The tunnel walls consist of six residues (F152, F208, Y306, G151, H180, and M274) that occupy four methylene groups of the substrate. At the end of the tunnel lies the catalytic machinery where the zinc ion bound to D178, D267, and H180 coordinates the deacetylation process. Here, the zinc ion and Y306 activate the amide carbonyl (C = O) of the substrate for a nucleophilic attack. D101 plays a critical role in substrate binding by directing conformational changes of the L2 loop from an unliganded form to a liganded form [26].




Figure 1. Crystal structure of HDAC8. (A) Head-to-head dimeric arrangement of HDAC8 (PDB ID: 2V5W [27]). Two monomers of HDAC8 are shown in light and dark yellow. Zinc and potassium are represented as grey and purple spheres, respectively (B) Liganded form of HDAC8 (PDB ID: 1T67 [15]). L2 loop and MS-344 are colored grey and green, respectively. (C) Catalytic machinery of HDAC8 (PDB ID: 1T64 [15]). Zinc ion is coordinated to three HDAC8 residues and two oxygen atoms of TSA. The zinc coordination shell is indicated by dashed lines. (D) Active site of HDAC8 (PDB ID: 1T64 [15]). Six key residues form the hydrophobic tunnel that occupies two TSA molecules.

3. Regulation of HDAC8 Expression and Activity

HDAC8 expression can be modulated by regulating the level of transcription, translation, or degradation (Figure 2). In terms of transcription, several transcription factors have been identified to bind to the promoter of HDAC8 and activate transcription. These transcription factors include forkhead box protein O1/3 (FOXO1/3), SRY-box transcription factor 4 (SOX4), cAMP responsive element binding protein 1 (CREB1), sterol regulatory element-binding protein 1 (SREBP-1), and Yin Yang 1 (YY1) [28–32]. HDAC8 translation can be repressed by microRNAs (miRNAs) interacting with the 3′ untranslated regions (3′UTR) of the target mRNA [33]. Specifically, miR-451(a), miR-216b-5p, miR-144-3p, miR-483-3p, miR-21-3p, miR-93, miR-95-5p, and miR-455-3p target HDAC8 mRNA to decrease its expression [34–43]. Furthermore, HDAC8 expression levels depend on the degradation

system. In lung cancer cells, cAMP signaling increases HDAC8 protein levels by inhibiting PI3K-AKT-JNK-mediated autophagy and proteasomal degradation [44].




Figure 2. Schematic representation of human HDAC8 and its regulation. HDAC8 is upregulated by transcription factors and downregulated by miRNA, autophagy, and proteasomal degradation.

As previously mentioned, AMPK-mediated phosphorylation of HDAC8 regulates its subcellular localization. However, phosphorylation of HDAC8 can also negatively regulate its deacetylase activity. cAMP-dependent protein kinase A (PKA)-mediated phosphorylation of HDAC8 at Ser39 suppresses HDAC8 catalytic activity, both in vitro and in vivo [45]. Nakayama et al. demonstrated that PKA inhibitor H89 suppresses HDAC8 phosphorylation, activating HDAC8 and reducing histone acetylation, whereas PKA activator forskolin hyperphosphorylates HDAC8, suppressing HDAC8 activity and increasing histone acetylation [Nakayama, 2017 #571].

4. HDAC8 Substrates

HDAC8 deacetylates histones preferentially at histone H3 lysine 9 (H3K9) and H3 lysine 27 (H3K27) and regulates the transcription of its target genes. Multiple non-histone substrates such as SMC3, p53, and estrogen-related receptor alpha (ERR α) have also been identified (Figure 3). HDAC8 deacetylates its substrates and regulates protein stability and activity. Although multiple HDAC8 substrates have been identified so far, the development of biochemical investigation techniques potentiates the discovery of other HDAC8 substrates [46,47].




Figure 3. Schematic representation of histone and non-histone substrates of HDAC8. HDAC8 deacetylates histones and suppresses transcription of target genes. HDAC8 also deacetylates non-histone substrates such as SMC3, α -tubulin, cortactin, HSP20, p53, PKM2, AKT, ERR α , and c-Jun.

4.1. Histone Substrates

HDAC8 deacetylates all core histones *in vitro* [11,12]. However, following studies indicated limited histone deacetylating activity of HDAC8 *in vivo*. No significant changes in histone acetylation levels were observed when HDAC8 was overexpressed or inhibited [13,48,49]. It has been suggested that the failure in detecting *in vivo* histone substrates arises from limitations in experimental methods or from the compensation of other HDACs that mask the deacetylase activity of HDAC8. [14]. Indeed, specific antibodies could detect the distinct sites of histones deacetylated by endogenous and ectopically expressed HDAC8, preferentially at H3K9ac and H3K27ac [50–54]. HDAC8-mediated deacetylation of H3/H4 histones at promoter or enhancer regions is involved in transcriptional repression of several genes such as interferon beta 1 (*IFNB1*), suppressor of cytokine signaling 1/3 (*SOCS1/3*), sirtuin 7 (*SIRT7*), mitogen-activated protein kinase kinase 3 (*MAP2K3*), C-C motif chemokine 4 (*CCL4*), inhibitor of DNA binding 2 (*ID2*), BCL2 interacting protein 3 (*BNIP3*), and metastatic lymph node 64 (*MLN64*) [54–60] (Table 1).

Table 1. HDAC8-mediated transcription repression of target genes.

Gene	Region	Histone Substrate	Cells	Reference
IFNB1	promoter	H3/H4	Macrophages	[55]
SOCS1/3	promoter	H3/H4	Erythroleukemia cells	[56]
SIRT7	promoter	H4	BC cells	[57]
MAP2K3	promoter	H3K9 and H3K27	Keratinocytes	[58]
CCL4	enhancer	H3K27	HCC cells	[54]
ID2	enhancer	H3K27	HCC cells	[59]
BNIP3	N/A	H3K27	TIR cells	[60]
MLN64	N/A	H3K27	TIR cells	[60]

4.2. Non-Histone Substrates

4.2.1. SMC3

HDAC8 interacts with and deacetylates various non-histone proteins. SMC3 is a unique substrate of HDAC8, first reported in 2012 [61]. SMC3 is a subunit of cohesin that is acetylated at Lys105 and Lys106 by the establishment of sister chromatid cohesion N-acetyltransferase 1/2 (ESCO1/2) and deacetylated by HDAC8 (Table 2) [62]. Deacetylation of SMC3 is crucial for cohesin-related functions such as sister chromatid cohesion, genome organization, and transcriptional regulation. Deacetylation of SMC3 enables proper dissolution of the cohesin complex so that it can be recycled for the following cell cycle. Loss of HDAC8 activity results in the accumulation of acetylated SMC3 and the retention of pro-cohesive elements, consequently disrupting the cell cycle [61]. HDAC8 also plays an important role in chromatin organization by regulating the size of chromatin architectural stripes and chromatin loops. Deacetylation of SMC3 by HDAC8 restarts the looping reaction that was restricted when the chromatin loops were bound to PDS5 cohesin-associated factor A (PDS5A) under SMC3 acetylation [63].

4.2.2. Tumor Suppressors

p53 is often referred to as the “guardian of the genome” and regulates multiple cellular events such as cell cycle progression and apoptosis [64]. Acetylation of p53 is crucial for its stabilization and activation and is mediated by CREB-binding protein (CBP)/p300, CBP/p300-associated factor (PCAF), males-absent on the first (MOF), monocytic leukemic zinc finger (MOZ), and Tat-interactive protein 60 (TIP60). In addition to HDAC8, other HDACs such as HDAC1, HDAC6, SIRT1, and SIRT3 have been previously identified to deacetylate p53 [65]. Due to the pivotal role of p53 as a tumor suppressor, p53 activation through HDAC8 inhibition is a potential therapeutic strategy and has been shown to be effective in ovarian cancer, hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML) [28,66–68]. So far, HDAC8 has been identified to deacetylate p53 at Lys381 and Lys382 [66–68]. Using combined analysis of chemical tools and proteomics, another tumor suppressor, AT-rich interactive domain-containing protein 1A (ARID1A), has been introduced as an unbiased candidate substrate of HDAC8. HDAC8 inhibition through PCI-34051 treatment greatly reduces ARD1A acetylation and in vitro enzymatic deacetylation experiment showed that recombinant HDAC8 deacetylates synthetically acetylated ARID1A peptide [48].

4.2.3. Kinases

Pyruvate kinase isoenzyme type M2 (PKM2) is a central regulator of signaling pathways that plays a dominant role in cancer development and progression. PTMs such as phosphorylation, oxidation, and acetylation are known to affect PKM2 activity [69]. Accordingly, HDAC8-mediated deacetylation of PKM2 at Lys62 residue regulates its stability, activity, and localization to the nucleus [70]. Furthermore, protein kinase B (PKB), also known as AKT, is a key player in the signal transduction pathways, that is deacetylated by HDAC8 at Lys426. AKT Lys426 to Arg mutant (K426R, lysine deacetylation mimic) increases GSK-3 β phosphorylation while AKT Lys426 to Gln mutant (K426Q, lysine acetylation

mimic) reduces GSK-3 β phosphorylation, indicating that HDAC8-mediated deacetylation is crucial for the phosphorylation and activation of AKT [71].

4.2.4. Cytoskeletal Proteins

Major targets of HDAC6, such as α -tubulin and cortactin, are also substrates of HDAC8 [72,73]. Acetylation of α -tubulin at Lys40 is mediated by alpha-tubulin N-acetyltransferase (α TAT1)/MEC-17 [74,75]. Deacetylation of α -tubulin is mainly mediated by HDAC6, but HDAC8 has also recently been characterized to deacetylate α -tubulin [76]. In HeLa cells, HDAC8 is significantly overexpressed and potentially takes over the function of HDAC6 to become the major deacetylase of α -tubulin [76]. Cortactin is an actin-binding protein that is acetylated by PCAF on nine lysines (Lys87, Lys124, Lys161, Lys189, Lys198, Lys235, Lys272, Lys309, and Lys319) within the repeat region. Acetylation of cortactin has shown to inhibit actin polymerization by decreasing its association with F-actin [73]. HDAC8 was identified to mediate the deacetylation of cortactin, enhancing actin filament polymerization and smooth muscle contraction [77]. HDAC8 is also involved in the regulation of an actin-severing protein, cofilin. HDAC8 deacetylates heat shock protein 20 (HSP20) at Lys160 and interacts with cofilin to form the HDAC8/HSP20/cofilin complex. Although the precise mechanism is yet to be uncovered, Karolczak-Bayatti et al. suggested that acetylated HSP20 reduces inactive phospho-cofilin levels, thereby affecting actin dynamics [21].

4.2.5. Transcription Factors

ERR α is an orphan nuclear receptor (NR) that is mainly involved in cellular metabolism by regulating the transcription of metabolic genes [78]. Acetylation of ERR α is catalyzed by PCAF at four lysines (Lys129, Lys138, Lys160, and Lys162) located within the zinc finger and C-terminal extension (CTE) of the DNA-binding domain (DBD). ERR α acetylation reduces its DNA-binding and transcriptional activity. HDAC8 directly deacetylates ERR α , thereby reactivating its transcriptional activity [79]. c-Jun is an oncogenic transcription factor that belongs to the activating protein 1 (AP-1) family [80]. Among three potential acetylation sites (Lys268, Lys271, and Lys273), HDAC8 deacetylates c-Jun at Lys273 and increases its transcriptional activity in melanoma cells [81]. HDAC8 also interacts with other binding partners, such as CREB and RUNX family transcription factor 2 (RUNX2) and represses their activities [50,82].

Table 2. HDAC8 substrates and interacting partners.

	Protein	Deacetylation Site	Effect	Related Disease	Reference
Substrate	SMC3	Lys105 and Lys106	Recycling of cohesin complex Chromatin organization	CdLS	[61,63,83]
	p53	Lys381 and Lys382	Repressed stability and activity	Ovarian cancer HCC	[28,66–68]
	ARD1A	N/A	N/A	N/A	[48]
	PKM2	Lys62	Nuclear localization Glucose metabolism	HCC	[70]
	AKT	Lys426	Enhanced stability and activity	BC	[71]
	α -Tubulin	Lys40	Deregulation of microtubule structural organization Cell migration	Cervical cancer Glioma DMD	[76,84,85]
	Cortactin ¹	Nine lysines within the repeat region ¹	Actin filament polymerization Smooth muscle contraction	N/A	[77]
	HSP20	Lys160	Actin filament polymerization Smooth muscle contraction	Premature birth	[21]
	ERR α ¹	Four lysines within the DBD ¹	Enhanced transcriptional activity	N/A	[79].
	c-Jun	Lys273	Enhanced transcriptional activity	Melanoma	[81]
Interacting Partner	CREB [82], PP1 [82], RUNX2 [50], Gal-3 [86], CM [68], Cofilin [21], HSP70 [87], EST1B [87], α -SMA [88]				

¹ Potential HDAC8 deacetylation sites. Further verification is required.

5. HDAC8 in Cancer

HDAC8 plays a multifunctional role in cancer progression (Figure 4). By acting on histones and non-histone substrates, HDAC8 stimulates tumor growth and metastasis by enhancing cell proliferation, suppressing apoptosis, and activating epithelial-mesenchymal transition (EMT). HDAC8 is also deeply involved in the process of immune evasion and drug resistance, which are crucial for tumor progression. Accordingly, genetic ablation or pharmacological inhibition of HDAC8 demonstrates anti-cancer effects in various types of cancer.




Figure 4. Schematic representation of pathological functions of HDAC8 in cancer. HDAC8 promotes tumor growth by enhancing tumor cell proliferation and suppressing apoptosis. HDAC8 also enhances metastasis and is involved in drug resistance and immune evasion.

5.1. Cancer Cell Proliferation and Apoptosis

HDAC8 is overexpressed in cancers such as gastric cancer, HCC, oral squamous cell carcinoma, and childhood acute lymphoblastic leukemia. [67,89–91]. Especially, HDAC8 expression is positively correlated with advanced-stage diseases and poor outcomes in neuroblastoma and breast cancer (BC) [71,92]. Conversely, decreased expression of HDAC8 is associated with poor prognosis in metastatic melanoma and intrahepatic cholangiocarcinoma [23,93]. Nevertheless, numerous studies support the tumorigenic role of HDAC8 and confirmed that genetic ablation or pharmacological inhibition of HDAC8 reduces cell proliferation, suppresses colony formation, and induces cell cycle arrest in cancer [25,29,36,84,89,90,92,94,95]. Upregulation of apoptosis is also frequently observed when cancer cells are treated with HDAC8is [94,96–99]. HDAC8 depletion or inhibition induces p53/p21-mediated apoptosis in HCC cells, Bcl2 modifying factor-mediated apoptosis in gastric cancer and colon cancer cells, and caspase-dependent apoptosis in T cell lymphomas [31,49,89,100].

Several studies have investigated the molecular mechanism of HDAC8-induced tumor cell proliferation. Zhang et al. presented that HDAC8 deacetylates the Lys62 residue of PKM2 and facilitates its transport to the nucleus, where it binds to β -catenin, promoting cyclin D1 (*CCND1*) gene transcription and cell cycle progression [70]. In myeloproliferative neoplasm (MPN) cells, HDAC8 suppresses the expression of SOCS1 and SOCS3. This hyperactivates Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling and promotes the oncogenesis of MPNs. Consistently, HDAC8 knockdown increases the expression of SOCS1/3 and suppresses cell proliferation [56]. HDAC8 binds to the human ortholog of the yeast ever-shorter telomeres 1B (hEST1B) and protects it from ubiquitin-mediated degradation. Phosphorylated HDAC8 recruits HSP70 to the hEST1B-carboxy-terminus of the Hsc70-interacting protein (CHIP) complex, which inhibits CHIP E3 ligase-mediated degradation of hEST1B. Because telomerase activity is responsible for senescence escape in tumor cells, these results suggest that HDAC8-mediated stability of hEST1B may contribute to increased tumor cell proliferation [87].

p53 has been intensively studied in HDAC8-related tumor growth. In AML, the inversion of chromosome 16, *inv(16)*, gives rise to aberrant production of fusion protein CBF β -SMMHC (CM). CM interacts with both HDAC8 and p53 and mediates the deacetylation and inactivation of p53, promoting leukemia stem cell (LSC) transformation and cell survival. Accordingly, inhibition of HDAC8 induces apoptosis by restoring p53 acetylation and activation [68]. The effect of HDAC8 on p53 is not confined to wild-type p53. Mutant p53 undermines the tumor suppressive function of wild-type p53 and promotes tumor cell survival. In triple-negative breast cancer (TNBC) cells, inhibition of HDAC8 increases the acetylation of YY1, decreasing its transcriptional activity and downregulating mutant p53 transcription, consequently repressing tumor cell proliferation [101]. In another research, HDAC8 knockdown decreased the transcription of mutant p53 by decreasing HOXA5 expression and activity, subsequently inhibiting cell proliferation [102]. Contrary to previous studies, however, Singh et al. reported that HDAC8 activator TM-2-51 enhances the expression of p53, inducing apoptosis and inhibiting cell growth in p53 wild-type neuroblastoma cells. [103].

5.2. Metastasis

5.2.1. Breast Cancer Metastasis

HDAC8 is highly expressed in BC relative to other cancers [17]. TCGA database analysis indicated that HDAC8 expression increases with the grade and stage of BC patients. Additionally, BC cell models with overexpressed HDAC8 are more likely to metastasize to the lungs [71]. MDA-MB-231, one of the most invasive BC cell lines, expresses higher levels of HDAC8 than MCF-7, a less invasive BC cell line [104].

HDAC8 triggers BC metastasis *in vitro* and *in vivo*. BC migration is enhanced when HDAC8 is overexpressed and significantly suppressed upon HDAC8 knockdown or PCI-34051 treatment [105,106]. HDAC8 downregulation also decreases mesenchymal cell makers such as fibronectin, vimentin, matrix metalloproteinase-9 (MMP-9), and MMP-2. In addition, detyrosination of α -tubulin, an important marker of migration and invasion of cancer cells, is decreased upon HDAC8 inhibition in BC cells. Mice inoculated with MDA-MB-231 stably expressing HDAC8 present a greater number of lung tumors [71]. Furthermore, in 4T1 BC xenograft, PCI-34051 treatment significantly decreases lung metastatic nodules compared to that of the control mouse [57].

HDAC8 promotes metastasis through several mechanisms. In TNBC cells, analysis of several migration-related signal factors revealed that yes-associated protein 1 (YAP), an important Hippo pathway target that drives metastasis, is upregulated upon HDAC8 overexpression. HDAC8 stabilizes the expression and localization of YAP by suppressing its phosphorylation at Ser127. Depletion or inhibition of YAP using siRNA or verteporfin, respectively, abolishes HDAC8-induced cell migration, suggesting that HDAC8 regulates TNBC migration by enhancing YAP expression. Interestingly, HDAC8-dependent regulation of YAP was not observed in non-TNBC cells [105]. Investigation of EMT transcription

factors, including TWIST, ZEB1, and SNAIL, revealed that only SNAIL is upregulated upon HDAC8 overexpression. PCI-34051 treatment or HDAC8 knockdown decreases the expression of SNAIL and its nuclear localization, while overexpression of SNAIL attenuates EMT suppression effects of PCI-34051. These results indicate that HDAC8 promotes metastasis via the regulation of SNAIL. Further investigation demonstrated that HDAC8 deacetylates AKT, increasing its phosphorylation and activation. AKT, in turn, phosphorylates and suppresses the catalytic activity of GSK-3 β . Downregulation of GSK-3 β activity represses SNAIL phosphorylation, enhancing protein stabilization and nuclear localization of SNAIL [71]. Transforming growth factor- β (TGF- β) signaling also promotes metastasis in BC. HDAC8 is a co-factor of a positive feedback loop that hyperactivates TGF- β signaling by suppressing SIRT7 transcription. HDAC8 inhibition suppresses BC cell migration induced by TGF- β 1 while SIRT7 knockdown attenuates this effect in vivo and in vitro, implicating that HDAC8 inhibition suppresses metastasis by enhancing SIRT7 transcription [57]. These findings show that HDAC8 plays an important role in breast cancer metastasis.

5.2.2. Metastasis in Other Cancers

HDAC8 has been reported to be involved in metastasis of other cancers besides BC. In neuroblastoma, HDAC8 is the only enzyme among 11 HDAC isoforms (HDAC1-11) that significantly correlates with the advanced stage [92]. In cervical cancer cells, PCI-34051 treatment significantly reduces cell migration [76]. In prostate cancer, HDAC8 promotes cancer metastasis by repressing the expression of maspin, a tumor suppressor that regulates cell migration and invasion. Knockdown of HDAC8 rescues maspin expression by increasing p53 acetylation and its binding with maspin promoter, enhancing maspin transcription and significantly reducing migration in prostate cancer cells [107]. HDAC8 promotes glioma migration by regulating the acetylation levels of α -tubulin, which is important in microtubule structural organization and cell migration. HDAC8 inhibition by PCI-34051 treatment elevates acetylated α -tubulin and reduces cell migration in glioma cells [84]. HDAC8 upregulates EMT in HCC by binding to the enhancer region of inhibitor of DNA binding 2 (ID2) and decreasing its transcription. ID2 suppresses EMT through direct interaction with TWIST. Consistently, downregulation of ID2 using ID2-AS1, a long non-coding RNA (lncRNA) that enhances ID2 transcription via blocking HDAC8 occupancy at the ID2 enhancer region, inhibits HCC invasion and migration in vitro and in vivo [59].

5.3. Immune Evasion

HDAC8 has been recognized to be involved in several strategies of immune evasion. Glioma creates a tumor microenvironment (TME) that supports tumor growth by switching glioma-associated microglia/macrophages (GAMs) to the anti-inflammatory phenotype as well as impairing natural killer (NK) cell recruitment and activity. HDAC8 inhibition by PCI-34051 treatment switches GAMs to the pro-inflammatory/anti-tumoral phenotype. PCI-34051 treatment also enhances the expression of natural killer group 2D (NKG2D) ligands that trigger the cytotoxic activity of NK cells and increases infiltration of CD69⁺ and NKG2D⁺ NK cells in glioma tumor mass [84]. In mantle cell lymphoma (MCL), HDAC8 inhibition has been observed to increase interferon-gamma (IFN γ)-producing NK cells [99].

Immunosuppressive TME and insufficient tumor-infiltrating lymphocytes limit the effectiveness of immune-checkpoint blockade (ICB) in HCC patients. Yang et al. proposed an HDAC8-regulated enhancer program that promotes T cell exclusion from the tumor, attenuating responsiveness to programmed death-ligand 1 (PD-L1) blockade in HCC. Chromatin profiling revealed that HDAC8 silences enhancers of the genes involved in immune-related functions such as T cell-trafficcking chemokines via H3K27 deacetylation. Downregulation of HDAC8 restores H3K27 acetylation, promoting T-cell trafficking chemokine production and intratumoral CD8⁺ T cell infiltration. HDAC8 inhibition in combination with ICB therapy using anti-PD-L1 antibodies induces effective and durable anti-tumor responses [54]. Moreover, HDAC8 suppresses anti-tumor immunity in melanoma cells by reducing the expression of PD-L1. HDAC8 inhibition upregulates HOXA5/STAT3-mediated transcrip-

tional activation of PD-L1 encoding gene, *CD274*, thereby enhancing anti-tumor T-cell response in melanoma cells [108].

5.4. Drug Resistance

5.4.1. Chemotherapy

Paclitaxel resistance in BC patients is largely attributed to TGF- β activation. HDAC8 promotes paclitaxel resistance by hyperactivating TGF- β signaling via SIRT7-SMAD4 axis. HDAC8 inhibition sensitizes BC cells and xenograft mouse models to paclitaxel by rescuing SIRT7 expression. Clinically, patients with high HDAC8 expression show worse prognosis after receiving chemotherapy, further highlighting the importance of HDAC8 in drug resistance [57].

HDAC8 is also associated with temozolomide (TMZ) resistance in GBM cells. HDAC8 is significantly upregulated in TMZ-resistant GBM cell lines compared to the parental GBM cells. NBM-BMX (BMX), an HDAC8i, greatly enhances the cytotoxic effect of TMZ in resistant cells. Combination treatment of BMX and TMZ suppresses cell proliferation by the Wnt/ β -catenin/GSK-3 β pathway, induces cell cycle arrest in G0/G1, and promotes p53-mediated apoptosis. Furthermore, BMX and TMZ treatment attenuates GBM stem cell characteristics and reduces protein levels of stem cell makers such as CD44, SOX2, and CD133 to overcome TMZ resistance [109].

In neuroblastoma, HDAC8 inhibition increases sensitivity to doxorubicin (Dox). HDAC8 inhibition using siRNA upregulates miR-137 which increases Dox sensitivity in neuroblastoma cells by reducing the expression of constitutive androstane receptor and its target, multidrug resistance protein 1 (MDR1). Subsequently, depletion of HDAC8 downregulates the expression of MDR1 and elevates Dox sensitivity in neuroblastoma cells, while knockdown of miR-137 reverses these effects [110].

In AML, HDAC8 promotes daunorubicin (DNR) resistance via regulating interleukin-6 (IL-6) and IL-8 expression. DNR-resistant AML cells show significant overexpression of HDAC8, IL-6, and IL-8. Targeted inhibition of HDAC8 increases DNR sensitivity, while ectopic expression of IL-6 and IL-8 reverses siHDAC8-induced DNR sensitivity. A mechanism study demonstrated that HDAC8 could directly bind to the RELA promoter and enhance its transcription, which increases the expression of IL-6 and IL-8 in DNR-resistant AML cells [111]. HDAC8 inhibition has also been shown to significantly enhance the sensitivity of AML stem cells to cytarabine, another frontline chemotherapeutic agent used for AML [68].

5.4.2. Targeted Therapy

HDAC8 mediates BRAF inhibitor (BRAFi) resistance in melanoma cells. HDAC8 is consistently overexpressed in BRAFi-resistant melanoma cell lines, and ectopic expression of HDAC8 in melanoma cells increases BRAFi tolerance. Moreover, HDAC8 overexpression significantly reduces BRAFi-induced apoptosis by suppressing the pro-apoptotic protein, Bcl-2-like protein 11 (BIM), and stabilizing anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). Mass spectrometry-based phosphoproteomics revealed that HDAC8 drives BRAFi resistance through c-Jun deacetylation. HDAC8 deacetylates c-Jun and increases its transcriptional activity, subsequently enhancing receptor tyrosine kinase (RTK) and mitogen-activated protein kinase (MAPK) signaling. Introducing Lys273 to Arg (K273R) c-Jun mutant, which mimics consistent deacetylation, reduces BRAFi sensitivity in melanoma cells. Consistent with the *in vitro* data, co-targeting BRAF and HDAC8 showed synergistic anti-tumor effects in melanoma mouse models [81].

In melanoma and colon cancer cells, HDAC8 induces resistance to MEK1/2 inhibition by activating AKT signaling and promoting cell proliferation in the absence of MEK/ERK activation [112,113]. Indeed, Ha et al. demonstrated that MEK 1/2 inhibition by either lethal toxin (LT) or MEK1/2 inhibitor, U0126, enhances phosphorylation and activation of AKT, while PCI-34051 or siHDAC8 reverses these effects. Although the precise mechanism is yet to be clarified, it was suggested that HDAC8 activates the AKT pathway

in MEK1/2 inhibition-resistant cells by increasing the expression of phospholipase C- β 1 (PLCB1) and decreasing the expression of squamous cell carcinoma-1 (DESC1). PLCB1 knockdown or DESC1 overexpression mimics HDAC8 inhibition and suppresses AKT activation, preventing cell proliferation in resistant cells [113].

Mutation of internal tandem duplication (ITD) at FMS-like receptor tyrosine kinase-3 (FLT3) is one of the major mutations in AML. While several FLT3 tyrosine kinase inhibitors (TKI) have shown clinical significance, most patients experience only partial and transient responses [114]. FLT3 inhibition induces FOXO1- and FOXO3-associated HDAC8 upregulation, which inactivates p53 and drives TKI resistance in FLT3-ITD+ AML cells. Accordingly, the combination of HDAC8i, 22d, and FLT3 TKI enhances the elimination of FLT3-ITD+ AML and reduces leukemia-initiating capacity in vivo [28].

6. HDAC8 in Non-Cancer Disease

Pathological functions of HDAC8 go beyond cancer. HDAC8 participates in the pathogenesis of diseases such as CdLS, infectious disease, cardiovascular disease, pulmonary disease, gastrointestinal disease, hepatic disease, renal disease, neuronal disease, osteopathy, and myopathy [30,34,39,83,85,115–119]. Although the precise molecular mechanism is limited, HDAC8 inhibition suppresses the advancement of the diseases, demonstrating its potential as a therapeutic target.

6.1. CdLS and Infectious Diseases

CdLS is a severe genetic disorder characterized by distinctive facial dysmorphism, growth retardation, and cognitive impairment. Loss-of-function HDAC8 mutation is one of the five causative mutations of CdLS, and the increase in acetylated SMC3 drives both clinical and cellular features of CdLS [61,83]. HDAC8 is also associated with viral infections by regulating viral entry, replication, and host immune response [40,55,115]. Furthermore, targeting parasite-specific HDAC8 has therapeutic potential in treating parasitic diseases such as *Schistosoma mansoni* and *Mesocostoides corti* [120,121].

6.2. Cardiovascular Disease

Concerning cardiovascular diseases, HDAC8 is associated with the development of cardiac hypertrophy, fibrosis, inflammation, and hypertension. Ectopic expression of HDAC8 induces hypertrophy in cardiomyocytes and upregulates cardiac hypertrophy markers such as ACTA, ANP, BNP, and β -MHC. Overexpression of HDAC8 also increases the levels of phospho-AKT and phospho-GSK-3 β , activating the AKT/GSK-3 β pathway, which is important for growth control in the cardiovascular system [39]. In a separate study, Zhao et al. elucidated that HDAC8 stimulates cardiac hypertrophy by upregulating p38 MAPK. MAPK pathway is one of many pathways that are involved in promoting cardiac hypertrophy. Accordingly, HDAC8 inhibition by PCI-34051 suppresses p38 activation, attenuates markers of cardiac hypertrophy and fibrosis, and suppresses cardiac hypertrophy in vitro and in the isoproterenol-induced cardiac hypertrophy mouse model [122]. In the following research, HDAC8 was demonstrated to be involved in the proinflammatory RELA pathway and fibrosis-related TGF- β 1-SMAD2/3 pathway via the HDAC8-ACE1 axis. Consequently, PCI-34051 treatment alleviates heart failure-related features such as cardiac hypertrophy, pulmonary congestion, fibrosis, and inflammation in vitro and in the TAC-induced heart failure model [123]. Additionally, Kee et al. demonstrated the therapeutic benefits of HDAC8 inhibition in alleviating hypertension. PCI-34051 treatment decreases high blood pressure by reducing aortic wall thickness, increasing vascular relaxation, and attenuating inflammation in the Ang II-induced hypertension mouse model [124].

6.3. Pulmonary Disease

HDAC8 takes part in pulmonary hypertension, fibrosis, and inflammation [86,116,125]. HDAC8 is upregulated in various tissues and cells of patients with pulmonary arterial hypertension (PAH). Additionally, HDAC8 downregulation significantly suppresses KLF2

transcription, which plays an important role in driving PAH pathogenesis [116]. HDAC8 also contributes to the pathogenesis of pulmonary fibrosis. HDAC8 expression is increased in idiopathic pulmonary fibrosis lung tissues and normal human lung fibroblasts treated with the fibrogenic cytokine, TGF- β 1. siHDAC8 represses TGF- β 1-induced expression of profibrotic factors such as fibronectin and type 1 collagen and increases expression of antifibrotic factors such as peroxisome proliferator-activated receptor- γ (PPAR γ). Particularly, HDAC8 inhibition increases PPAR γ expression by restoring TGF- β 1-induced loss of H3K27ac at the *PPARG* enhancer. Moreover, NCC170, an HDAC8i, significantly decreases fibrosis score and downregulates the expression of profibrotic proteins in a bleomycin-induced pulmonary fibrosis mouse model [125].

6.4. Hepatic Disease

Cholestasis is a liver disease that arises when bile flow is blocked and leads to hepatotoxicity, inflammation, and fibrosis. Hepatic expression of HDAC8 is elevated in human and murine cholestasis models. SPA3014, an HDAC8i, ameliorates cholestatic liver injury by reducing necrotic damage, inflammation, and fibrosis in the liver of bile duct-ligated mice. In vitro studies demonstrated that SPA3014 attenuates hepatic fibrosis by suppressing the TGF- β signaling pathway [126]. Alcoholic hepatitis (AH) is a severe liver disease that arises from excessive alcohol consumption. In AH mice, ectopic expression of HDAC8 significantly exacerbates liver inflammation and increases proinflammatory mediators, such as TNF- α and IL-1 β [34].

6.5. Myopathy

HDAC8 mediates various myopathies, such as Duchenne muscular dystrophy (DMD), rheumatoid arthritis (RA), and osteoarthritis (OA). DMD is a genetic disorder characterized by progressive degeneration and weakening of the muscles. HDAC8 is overexpressed in myoblasts and myotubes derived from DMD patients. PCI-34051 treatment abrogates DMD pathological phenotype by increasing myosin and reducing pro-inflammatory cytokine. Moreover, PCI-34051 treatment upregulates the acetylation of cytoskeleton proteins, especially α -tubulin, rescuing the cytoskeleton architecture of DMD myotubes [85]. RA is an autoimmune disease that causes joint destruction. Inhibition of HDAC8 with butyrate reduces the severity of arthritis by regulating T_H17/T_{reg} balance, which is critical for maintaining immune homeostasis. Butyrate enhances the acetylation of ERR α , which suppresses its transcriptional activity, consequently upregulating the expression of carnitine palmitoyltransferase I (CPTI) and downregulating the expression of nuclear receptor subfamily 1, group D, member 1 (NR1D1). Butyrate-induced changes in CPTI and NR1D1 expression increase the number of anti-inflammatory T_{reg} cells and decrease the number of pro-inflammatory T_H17 cells, thereby attenuating rheumatoid inflammation [127]. OA is a degenerative joint disease characterized by cartilage destruction and impaired joint function. HDAC8 is upregulated in the OA model of rat articular chondrocytes (rACs) treated with IL-1 β . HDAC8 inhibition suppresses the expression of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4), ADAMTS-5, collagen type X (col X), and cyclooxygenase-2 (COX2), all of which are implicated in the pathogenesis of OA [128]. Furthermore, the knockdown of HDAC8 significantly increases the expression of the chondrogenic marker, SOX9, and greatly decreases the expression of degenerating marker, RUNX2, suggesting that HDAC8 can be targeted to treat osteoarthritis [42].

6.6. Other Diseases

HDAC8 inhibition is effective against neuroinflammation-mediated diseases. In an intrastriatal LPS-induced neuroinflammation mouse model, an HDAC8i 22d alleviates neurological deficits and reduces neuroinflammatory responses. The neuroprotection is mediated by suppressing glial activation, which is critical in the pathogenesis of neuroinflammation. Specifically, 22d decreases inflammatory enzymes and TNF- α production of microglial cells, partly resulting from the regulation of STAT1/3 and AKT activity [119].

Fibrous dysplasia (FD) is a genetic disorder characterized by the development of fibrous tissue in place of normal bone. *GNAS* mutations are frequently observed in FD cases and are considered to be the leading cause of the disease. HDAC8 is overexpressed in FD BMSCs due to *GNAS* mutation that activates the cAMP-CREB-HDAC8 axis. Upregulation of HDAC8 is involved in FD pathogenesis by enhancing proliferation and decreasing osteogenesis in BMSCs, which is mediated by HDAC8-induced repression of p53 and RUNX2, respectively. Accordingly, pharmacological inhibition and genetic downregulation of HDAC8 enhance the osteogenic potential in vitro and in vivo [30].

7. HDAC8-Selective Inhibitors

7.1. PCI-34051

PCI-34051 is an indole-based HDAC8i ($IC_{50} = 56$ nM) [129] that was developed by Pharmacyclics Inc. in 2008 (Table 3). It contains a metal-chelating hydroxamic acid group that potentially binds to metalloenzymes. It has more than 200-fold specificity for HDAC8 inhibition over other class I HDACs as well as HDAC6 and HDAC10 [49].

The combination effects of PCI-34051 with other therapeutic agents have been studied for anti-cancer effects. PCI-34051 exerts synergistic effects when combined with chemotherapy, such as paclitaxel in TNBC [57] and cytarabine in AML [130]. PCI-34051 also shows synergism with targeted therapy. PCI-34051 enhances anti-cancer effects when treated with ALK/MET inhibitor, crizotinib, in neuroblastoma cells, [131] nicotinamide phosphoribosyltransferase inhibitor, KPT-9274, in AML cells, [132] and HDAC6 inhibitor, ACY-241, in ovarian cancer cells [66]. Lastly, PCI-34051, in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants, has synergistic apoptotic effects in TRAIL-resistant colon cancer cells (DLD-1, WiDr) [133].

7.2. Aryl Hydroxamic Acids

Based on the crystal structure of HDAC8, six aryl hydroxamic acids (compounds 1–6) were synthesized in 2007. Unlike other HDAC inhibitors that have the canonical zinc binding group-linker-cap group, aryl hydroxamic acids are linkerless and target the unique sub-pocket located adjacent to M274 of the active site [134].

7.3. NBM-BMX (BMX)

BMX, synthesized from osthole [135], is the first and only HDAC8i that has entered the clinical trial. Currently, it is in a clinical trial for advanced cancer through oral administration (NCT03808870, NCT03726294). BMX has been reported to improve learning and memory in rat models [135] and to help restore TMZ sensitivity in glioblastoma [109].

7.4. WK2-16





Several ortho-aryl N-hydroxycinnamides were synthesized to target HDAC8 specifically. Among those compounds, (E)-N-hydroxy-4-methoxy-2-(biphenyl-4-yl) cinnamide (WK2-16 or 22d) effectively inhibits HDAC8 with an IC_{50} of 27.2 nM. WK2-16 exhibits greater anti-proliferative effects than PCI-34051 in human lung cancer cells (CL1-5, H1299, A549) without cytotoxicity in normal IMR-90 cells. In CL1-5 cells, the effect of WK2-16 is similar to that of SAHA [129]. Moreover, WK2-16 effectively synergizes with quizartinib (AC220), a second-generation TKI [136], in FLT3-ITD+ AML to exhibit anti-leukemia effects in vitro and in vivo. [28].

7.5. Dual Inhibitors

Dual inhibition of HDAC8 and MMP-2 is a potent anti-cancer therapeutic strategy for solid and hematological cancers [137,138]. The first chemical that inhibited both HDAC8 and MMP-2 was derived from an L-tyrosine scaffold. Hydroxamate compounds of L-tyrosine derivatives selectively inhibit MMP-2 and HDAC8 with equal potency as NNGH and SAHA, which are well-known inhibitors of MMP and HDAC, respectively [139]. In another study, a pharmacophore model was implemented to design an HDAC8/MMP-2

dual inhibitor. The newly synthesized molecule inhibits HDAC8 activity by interacting with specific amino acid residues (Tyr306, Ile34, Phe152, His143, and Cys153) at the acetate release channel. The inhibitor significantly suppresses cell migration and invasion of the A549 human lung cancer cell line [137].

Table 3. Chemical structures of HDAC8-selective inhibitors.

PCI-34051	Aryl Hydroxamic Acids Compound 6
	
BMX	WK2-16
	

8. Conclusions

Since its discovery in 2000, intensive studies have been conducted to characterize the structure and function of HDAC8 [11–13]. Functional studies of HDAC8 revealed that it plays a pivotal role in the pathogenesis of diseases such as cancer, CdLS, and infectious diseases and raised the need to find selective inhibitors that specifically target HDAC8. A study in 2004 identified the crystal structure of HDAC8 and accelerated the development of HDAC8is [25]. Since then, various HDAC8is have been developed, and a comprehensive review of HDAC8is has recently been reported [140]. Despite the substantial number of inhibitors developed, BMX is the only HDAC8i that has entered the clinical trial. Thus, further investigation to find an effective HDAC8i is needed. Recently, HDAC8-targeting proteolysis targeting chimeras (PROTACs) have been designed and have shown significant selectivity towards HDAC8, suggesting a novel therapeutic strategy [141,142].

Studies of HDAC8 are heavily concentrated on its role in cancer progression. HDAC8 is upregulated in cancer and is associated with tumor cell proliferation, apoptosis, metastasis, immune evasion, and drug resistance. Accordingly, HDAC8is have been tested alone or in combination in various types of cancer and have shown anti-cancer effects in vitro and in vivo. Recent studies have expanded our knowledge of HDAC8 in non-cancer diseases such as cardiovascular disease, pulmonary disease, and myopathy. HDAC8 was overexpressed in these diseases and associated with the upregulation of disease-related biomarkers. However, the molecular mechanisms underlying the pathogenesis of these diseases are poorly understood. Therefore, further studies are required to increase our understanding of HDAC8 in non-cancer diseases.

Here, we focused on the pathological function of HDAC8. However, some important discoveries have been made in the physiological functions of HDAC8. For instance, HDAC8 supports smooth muscle contraction by interacting with substrates such as α -SMA, cortactin, and cofilin [20,21,77]. HDAC8 is also involved in skeletal muscle and neural differentiation [143–145] as well as stem cell maintenance [50,146]. Nevertheless, the limited number of studies on the physiological function of HDAC8 suggests more studies should be conducted to explore novel substrates and functions of HDAC8 in normal physiology.

Multiple mechanisms regulate the expression and activity of HDAC8, and in turn, HDAC8 is involved in important cellular processes such as cell cycle, migration, and differentiation. The latest research on HDAC8 highlights the therapeutic potential of targeting HDAC8 to overcome diseases. Thus, further investigations on HDAC8 substrates, as well as effective HDAC8is, are required.

Author Contributions: Conceptualization, J.Y.K., H.C. and S.H.K.; investigation, J.Y.K. and H.C.; writing—original draft, J.Y.K., H.C. and S.H.K.; writing—review and editing, J.Y.K., H.C., G.W.K., J.Y. and S.H.K.; visualization, J.Y.K., Y.H.J. and S.W.L.; supervision, S.H.K.; project administration, S.H.K.; funding acquisition, G.W.K. and S.H.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (2018R1A6A1A03023718, 2019R1A2C1008619, and 2019H1A2A1076925) and by Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (HN21C0952, Republic of Korea).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare that they have no conflict of interest.

References

1. Chen, Z.; Li, S.; Subramaniam, S.; Shyy, J.Y.; Chien, S. Epigenetic Regulation: A New Frontier for Biomedical Engineers. *Annu. Rev. Biomed. Eng.* **2017**, *19*, 195–219. [[CrossRef](#)]
2. Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. *Signal Transduct. Target. Ther.* **2019**, *4*, 62. [[CrossRef](#)] [[PubMed](#)]
3. Annunziato, A.T.; Hansen, J.C. Role of histone acetylation in the assembly and modulation of chromatin structures. *Gene Expr.* **2000**, *9*, 37–61. [[CrossRef](#)]
4. Verdone, L.; Caserta, M.; Di Mauro, E. Role of histone acetylation in the control of gene expression. *Biochem. Cell Biol.* **2005**, *83*, 344–353. [[CrossRef](#)]
5. Romanowska, K.; Sobocka, A.; Rawluszko-Wieczorek, A.A.; Suchorska, W.M.; Golusinski, W. Head and Neck Squamous Cell Carcinoma: Epigenetic Landscape. *Diagnostics* **2020**, *11*, 34. [[CrossRef](#)]
6. Micelli, C.; Rastelli, G. Histone deacetylases: Structural determinants of inhibitor selectivity. *Drug Discov. Today* **2015**, *20*, 718–735. [[CrossRef](#)]
7. Wang, P.; Wang, Z.; Liu, J. Role of HDACs in normal and malignant hematopoiesis. *Mol. Cancer* **2020**, *19*, 5. [[CrossRef](#)] [[PubMed](#)]
8. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. *Nat. Rev. Genet.* **2009**, *10*, 32–42. [[CrossRef](#)]
9. Li, T.; Zhang, C.; Hassan, S.; Liu, X.; Song, F.; Chen, K.; Zhang, W.; Yang, J. Histone deacetylase 6 in cancer. *J. Hematol. Oncol.* **2018**, *11*, 111. [[CrossRef](#)]
10. Yang, X.J.; Seto, E. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. *Oncogene* **2007**, *26*, 5310–5318. [[CrossRef](#)] [[PubMed](#)]
11. Buggy, J.J.; Sideris, M.L.; Mak, P.; Lorimer, D.D.; McIntosh, B.; Clark, J.M. Cloning and characterization of a novel human histone deacetylase, HDAC8. *Biochem. J.* **2000**, *350*, 199–205. [[CrossRef](#)] [[PubMed](#)]
12. Hu, E.; Chen, Z.; Fredrickson, T.; Zhu, Y.; Kirkpatrick, R.; Zhang, G.F.; Johanson, K.; Sung, C.M.; Liu, R.; Winkler, J. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. *J. Biol. Chem.* **2000**, *275*, 15254–15264. [[CrossRef](#)]
13. Van den Wyngaert, I.; de Vries, W.; Kremer, A.; Neefs, J.; Verhasselt, P.; Luyten, W.H.; Kass, S.U. Cloning and characterization of human histone deacetylase 8. *FEBS Lett.* **2000**, *478*, 77–83. [[CrossRef](#)]
14. Chakrabarti, A.; Oehme, I.; Witt, O.; Oliveira, G.; Sippl, W.; Romier, C.; Pierce, R.J.; Jung, M. HDAC8: A multifaceted target for therapeutic interventions. *Trends Pharmacol. Sci.* **2015**, *36*, 481–492. [[CrossRef](#)] [[PubMed](#)]
15. Somoza, J.R.; Skene, R.J.; Katz, B.A.; Mol, C.; Ho, J.D.; Jennings, A.J.; Luong, C.; Arvai, A.; Buggy, J.J.; Chi, E.; et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. *Structure* **2004**, *12*, 1325–1334. [[CrossRef](#)]
16. Dowling, D.P.; Gattis, S.G.; Fierke, C.A.; Christianson, D.W. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function. *Biochemistry* **2010**, *49*, 5048–5056. [[CrossRef](#)]
17. Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; et al. Expression profile of class I histone deacetylases in human cancer tissues. *Oncol. Rep.* **2007**, *18*, 769–774. [[CrossRef](#)]

18. Ahn, M.Y. HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression. *Oncol. Lett.* **2018**, *16*, 6552–6560. [[CrossRef](#)]
19. Huang, C.; Shu, Y.; Zhu, Y.; Liu, H.; Wang, X.; Wen, H.; Liu, J.; Li, W. Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices. *Bioorg. Med. Chem.* **2022**, *68*, 116821. [[CrossRef](#)]
20. Waltregny, D.; De Leval, L.; Glénisson, W.; Tran, S.L.; North, B.J.; Bellahcène, A.; Weidle, U.; Verdin, E.; Castronovo, V. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. *Am. J. Pathol.* **2004**, *165*, 553–564. [[CrossRef](#)]
21. Karolczak-Bayatti, M.; Sweeney, M.; Cheng, J.; Edey, L.; Robson, S.C.; Ulrich, S.M.; Treumann, A.; Taggart, M.J.; Europe-Finner, G.N. Acetylation of heat shock protein 20 (Hsp20) regulates human myometrial activity. *J. Biol. Chem.* **2011**, *286*, 34346–34355. [[CrossRef](#)] [[PubMed](#)]
22. Takase, K.; Oda, S.; Kuroda, M.; Funato, H. Monoaminergic and neuropeptidergic neurons have distinct expression profiles of histone deacetylases. *PLoS ONE* **2013**, *8*, e58473. [[CrossRef](#)] [[PubMed](#)]
23. Wilmott, J.S.; Colebatch, A.J.; Kakavand, H.; Shang, P.; Carlino, M.S.; Thompson, J.F.; Long, G.V.; Scolyer, R.A.; Hersey, P. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. *Mod. Pathol.* **2015**, *28*, 884–894. [[CrossRef](#)] [[PubMed](#)]
24. Li, Y.; Liang, R.; Sun, M.; Li, Z.; Sheng, H.; Wang, J.; Xu, P.; Liu, S.; Yang, W.; Lu, B.; et al. AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation. *Cancer Lett.* **2020**, *478*, 82–92. [[CrossRef](#)] [[PubMed](#)]
25. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E.C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 15064–15069. [[CrossRef](#)]
26. Dowling, D.P.; Gantt, S.L.; Gattis, S.G.; Fierke, C.A.; Christianson, D.W. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. *Biochemistry* **2008**, *47*, 13554–13563. [[CrossRef](#)]
27. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfi, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. *EMBO Rep.* **2007**, *8*, 879–884. [[CrossRef](#)]
28. Long, J.; Jia, M.Y.; Fang, W.Y.; Chen, X.J.; Mu, L.L.; Wang, Z.Y.; Shen, Y.; Xiang, R.F.; Wang, L.N.; Wang, L.; et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD⁺ acute myeloid leukemia. *Blood* **2020**, *135*, 1472–1483. [[CrossRef](#)]
29. Higuchi, T.; Nakayama, T.; Arao, T.; Nishio, K.; Yoshie, O. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. *Blood* **2013**, *121*, 3640–3649. [[CrossRef](#)]
30. Xiao, T.; Fu, Y.; Zhu, W.; Xu, R.; Xu, L.; Zhang, P.; Du, Y.; Cheng, J.; Jiang, H. HDAC8, A Potential Therapeutic Target, Regulates Proliferation and Differentiation of Bone Marrow Stromal Cells in Fibrous Dysplasia. *Stem Cells Transl. Med.* **2019**, *8*, 148–161. [[CrossRef](#)]
31. Tian, Y.; Wong, V.W.; Wong, G.L.; Yang, W.; Sun, H.; Shen, J.; Tong, J.H.; Go, M.Y.; Cheung, Y.S.; Lai, P.B. Histone deacetylase HDAC8 promotes insulin resistance and β -catenin activation in NAFLD-associated hepatocellular carcinoma. *Cancer Res.* **2015**, *75*, 4803–4816. [[CrossRef](#)] [[PubMed](#)]
32. Fu, W.; Liang, D.; Wu, X.; Chen, H.; Hong, X.; Wang, J.; Zhu, T.; Zeng, T.; Lin, W.; Chen, S.; et al. Long noncoding RNA LINC01435 impedes diabetic wound healing by facilitating YY1-mediated HDAC8 expression. *iScience* **2022**, *25*, 104006. [[CrossRef](#)] [[PubMed](#)]
33. Gu, S.; Jin, L.; Zhang, F.; Sarnow, P.; Kay, M.A. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. *Nat. Struct. Mol. Biol.* **2009**, *16*, 144–150. [[CrossRef](#)] [[PubMed](#)]
34. Du, B.; Tan, X.H.; Cheng, L.; Wang, F.; Zhang, H.F. MiR-451a ameliorates alcoholic hepatitis via repressing HDAC8-mediated proinflammatory response. *Kaohsiung J. Med. Sci.* **2020**, *36*, 904–910. [[CrossRef](#)]
35. Pang, Y.; Li, L.; Yang, Y.; Shen, Y.; Xu, X.; Li, J. LncRNA-ANAPC2 and lncRNA-NEFM positively regulates the inflammatory response via the miR-451/npr2/hdac8 axis in grass carp. *Fish Shellfish. Immunol.* **2022**, *128*, 1–6. [[CrossRef](#)]
36. Menbari, M.N.; Rahimi, K.; Ahmadi, A.; Elyasi, A.; Darvishi, N.; Hosseini, V.; Mohammadi-Yeganeh, S.; Abdi, M. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression. *Life Sci.* **2019**, *237*, 116945. [[CrossRef](#)]
37. Wang, B.; Xu, L.; Zhang, J.; Cheng, X.; Xu, Q.; Wang, J.; Mao, F. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p. *Biomed. Pharmacother.* **2020**, *129*, 110268. [[CrossRef](#)]
38. Menbari, M.N.; Rahimi, K.; Ahmadi, A.; Mohammadi-Yeganeh, S.; Elyasi, A.; Darvishi, N.; Hosseini, V.; Abdi, M. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene. *J. Cell. Physiol.* **2020**, *235*, 2631–2642. [[CrossRef](#)]
39. Yan, M.; Chen, C.; Gong, W.; Yin, Z.; Zhou, L.; Chaugai, S.; Wang, D.W. miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. *Cardiovasc. Res.* **2015**, *105*, 340–352. [[CrossRef](#)]
40. Xia, B.; Lu, J.; Wang, R.; Yang, Z.; Zhou, X.; Huang, P. miR-21-3p Regulates Influenza A Virus Replication by Targeting Histone Deacetylase-8. *Front. Cell. Infect. Microbiol.* **2018**, *8*, 175. [[CrossRef](#)] [[PubMed](#)]
41. Yu, X.F.; Zou, J.; Bao, Z.J.; Dong, J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. *World J. Gastroenterol.* **2011**, *17*, 4711–4717. [[CrossRef](#)]

42. Mao, G.; Hu, S.; Zhang, Z.; Wu, P.; Zhao, X.; Lin, R.; Liao, W.; Kang, Y. Exosomal miR-95-5p regulates chondrogenesis and cartilage degradation via histone deacetylase 2/8. *J. Cell. Mol. Med.* **2018**, *22*, 5354–5366. [[CrossRef](#)] [[PubMed](#)]
43. Chen, W.; Chen, L.; Zhang, Z.; Meng, F.; Huang, G.; Sheng, P.; Zhang, Z.; Liao, W. MicroRNA-455-3p modulates cartilage development and degeneration through modification of histone H3 acetylation. *Biochim. Biophys. Acta* **2016**, *1863*, 2881–2891. [[CrossRef](#)]
44. Park, J.-Y.; Juhnn, Y.-S. cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells. *Biochem. Biophys. Res. Commun.* **2016**, *470*, 336–342. [[CrossRef](#)] [[PubMed](#)]
45. Lee, H.; Rezaei-Zadeh, N.; Seto, E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. *Mol. Cell. Biol.* **2004**, *24*, 765–773. [[CrossRef](#)] [[PubMed](#)]
46. Alam, N.; Zimmerman, L.; Wolfson, N.A.; Joseph, C.G.; Fierke, C.A.; Schueler-Furman, O. Structure-Based Identification of HDAC8 Non-histone Substrates. *Structure* **2016**, *24*, 458–468. [[CrossRef](#)]
47. Lopez, J.E.; Haynes, S.E.; Majmudar, J.D.; Martin, B.R.; Fierke, C.A. HDAC8 Substrates Identified by Genetically Encoded Active Site Photocrosslinking. *J. Am. Chem. Soc.* **2017**, *139*, 16222–16227. [[CrossRef](#)]
48. Olson, D.E.; Udeshi, N.D.; Wolfson, N.A.; Pitcairn, C.A.; Sullivan, E.D.; Jaffe, J.D.; Svinkina, T.; Natoli, T.; Lu, X.; Paulk, J.; et al. An unbiased approach to identify endogenous substrates of “histone” deacetylase 8. *ACS Chem. Biol.* **2014**, *9*, 2210–2216. [[CrossRef](#)]
49. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. *Leukemia* **2008**, *22*, 1026–1034. [[CrossRef](#)]
50. Fu, Y.; Zhang, P.; Ge, J.; Cheng, J.; Dong, W.; Yuan, H.; Du, Y.; Yang, M.; Sun, R.; Jiang, H. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity. *Int. J. Biochem. Cell Biol.* **2014**, *54*, 68–77. [[CrossRef](#)]
51. Pidugu, V.R.; Yarla, N.S.; Bishayee, A.; Kalle, A.M.; Satya, A.K. Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells. *Apoptosis* **2017**, *22*, 1394–1403. [[CrossRef](#)] [[PubMed](#)]
52. Biswas, S.; Reddy, N.D.; Jayashree, B.S.; Rao, C.M. Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer. *Adv. Pharmacol. Sci.* **2018**, *2018*, 4751806. [[CrossRef](#)] [[PubMed](#)]
53. Ha, S.-D.; Reid, C.; Meshkibaf, S.; Kim, S.O. Inhibition of interleukin 1 β (IL-1 β) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages. *J. Biol. Chem.* **2016**, *291*, 8745–8755. [[CrossRef](#)]
54. Yang, W.; Feng, Y.; Zhou, J.; Cheung, O.K.-W.; Cao, J.; Wang, J.; Tang, W.; Tu, Y.; Xu, L.; Wu, F. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. *Sci. Transl. Med.* **2021**, *13*, eaaz6804. [[CrossRef](#)]
55. Meng, J.; Liu, X.; Zhang, P.; Li, D.; Xu, S.; Zhou, Q.; Guo, M.; Huai, W.; Chen, X.; Wang, Q.; et al. Rb selectively inhibits innate IFN- β production by enhancing deacetylation of IFN- β promoter through HDAC1 and HDAC8. *J. Autoimmun.* **2016**, *73*, 42–53. [[CrossRef](#)]
56. Gao, S.-M.; Chen, C.-Q.; Wang, L.-Y.; Hong, L.-L.; Wu, J.-B.; Dong, P.-H.; Yu, F.-J. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. *Exp. Hematol.* **2013**, *41*, 261–270. [[CrossRef](#)]
57. Tang, X.; Li, G.; Su, F.; Cai, Y.; Shi, L.; Meng, Y.; Liu, Z.; Sun, J.; Wang, M.; Qian, M.; et al. HDAC8 cooperates with SMAD3/4 complex to suppress *SIRT7* and promote cell survival and migration. *Nucleic Acids Res.* **2020**, *48*, 2912–2923. [[CrossRef](#)]
58. Sawada, Y.; Nakatsuji, T.; Dokoshi, T.; Kulkarni, N.N.; Liggins, M.C.; Sen, G.; Gallo, R.L. Cutaneous innate immune tolerance is mediated by epigenetic control of MAP2K3 by HDAC8/9. *Sci. Immunol.* **2021**, *6*, eabe1935. [[CrossRef](#)] [[PubMed](#)]
59. Zhou, Y.; Huan, L.; Wu, Y.; Bao, C.; Chen, B.; Wang, L.; Huang, S.; Liang, L.; He, X. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. *Cancer Lett.* **2020**, *469*, 399–409. [[CrossRef](#)] [[PubMed](#)]
60. Ha, S.D.; Han, C.Y.; Reid, C.; Kim, S.O. HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages. *J. Immunol.* **2014**, *193*, 1333–1343. [[CrossRef](#)]
61. Deardorff, M.A.; Bando, M.; Nakato, R.; Watrin, E.; Itoh, T.; Minamino, M.; Saitoh, K.; Komata, M.; Katou, Y.; Clark, D.; et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* **2012**, *489*, 313–317. [[CrossRef](#)]
62. Dasgupta, T.; Antony, J.; Braithwaite, A.W.; Horsfield, J.A. HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells. *J. Biol. Chem.* **2016**, *291*, 12761–12770. [[CrossRef](#)]
63. Van Ruiten, M.S.; van Gent, D.; Cacciatore, A.S.; Fauster, A.; Willems, L.; Hekkelman, M.L.; Hoekman, L.; Altelaar, M.; Haarhuis, J.H.I.; Brummelkamp, T.R.; et al. The cohesin acetylation cycle controls chromatin loop length through a PDS5A brake mechanism. *Nat. Struct. Mol. Biol.* **2022**, *29*, 586–591. [[CrossRef](#)]
64. Lane, D.P. p53, guardian of the genome. *Nature* **1992**, *358*, 15–16. [[CrossRef](#)]
65. Liu, Y.; Tavana, O.; Gu, W. p53 modifications: Exquisite decorations of the powerful guardian. *J. Mol. Cell. Biol.* **2019**, *11*, 564–577. [[CrossRef](#)]
66. Kim, J.Y.; Han, S.Y.; Yoo, J.; Kim, G.W.; Jeon, Y.H.; Lee, S.W.; Park, J.; Kwon, S.H. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells. *Int. J. Mol. Sci.* **2022**, *23*, 8645. [[CrossRef](#)]
67. Wu, J.; Du, C.; Lv, Z.; Ding, C.; Cheng, J.; Xie, H.; Zhou, L.; Zheng, S. The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. *Dig. Dis. Sci.* **2013**, *58*, 3545–3553. [[CrossRef](#)]

68. Qi, J.; Singh, S.; Hua, W.-K.; Cai, Q.; Chao, S.-W.; Li, L.; Liu, H.; Ho, Y.; McDonald, T.; Lin, A.; et al. HDAC8 inhibition specifically targets Inv (16) acute myeloid leukemic stem cells by restoring p53 acetylation. *Cell Stem Cell* **2015**, *17*, 597–610. [[CrossRef](#)]
69. Prakasam, G.; Iqbal, M.A.; Bamezai, R.N.K.; Mazurek, S. Posttranslational Modifications of Pyruvate Kinase M2: Tweaks that Benefit Cancer. *Front. Oncol.* **2018**, *8*, 22. [[CrossRef](#)]
70. Zhang, R.; Shen, M.; Wu, C.; Chen, Y.; Lu, J.; Li, J.; Zhao, L.; Meng, H.; Zhou, X.; Huang, G.; et al. HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma. *Cell Death Dis.* **2020**, *11*, 1036. [[CrossRef](#)] [[PubMed](#)]
71. An, P.; Chen, F.; Li, Z.; Ling, Y.; Peng, Y.; Zhang, H.; Li, J.; Chen, Z.; Wang, H. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3 β /Snail signals. *Oncogene* **2020**, *39*, 4956–4969. [[CrossRef](#)]
72. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. HDAC6 is a microtubule-associated deacetylase. *Nature* **2002**, *417*, 455–458. [[CrossRef](#)]
73. Zhang, X.; Yuan, Z.; Zhang, Y.; Yong, S.; Salas-Burgos, A.; Koomen, J.; Olashaw, N.; Parsons, J.T.; Yang, X.-J.; Dent, S.R.; et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. *Mol. Cell* **2007**, *27*, 197–213. [[CrossRef](#)] [[PubMed](#)]
74. Shida, T.; Cueva, J.G.; Xu, Z.; Goodman, M.B.; Nachury, M.V. The major α -tubulin K40 acetyltransferase α TAT1 promotes rapid ciliogenesis and efficient mechanosensation. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 21517–21522. [[CrossRef](#)] [[PubMed](#)]
75. Akella, J.S.; Wloga, D.; Kim, J.; Starostina, N.G.; Lyons-Abbott, S.; Morrisette, N.S.; Dougan, S.T.; Kipreos, E.T.; Gaertig, J. MEC-17 is an α -tubulin acetyltransferase. *Nature* **2010**, *467*, 218–222. [[CrossRef](#)] [[PubMed](#)]
76. Vanaja, G.R.; Ramulu, H.G.; Kalle, A.M. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6. *Cell Commun. Signal.* **2018**, *16*, 20. [[CrossRef](#)]
77. Li, J.; Chen, S.; Cleary, R.A.; Wang, R.; Gannon, O.J.; Seto, E.; Tang, D.D. Histone deacetylase 8 regulates cortactin deacetylation and contraction in smooth muscle tissues. *Am. J. Physiol. Cell Physiol.* **2014**, *307*, C288–C295. [[CrossRef](#)]
78. Tran, A.; Scholtes, C.; Songane, M.; Champagne, C.; Galarneau, L.; Levasseur, M.-P.; Fodil, N.; Dufour, C.R.; Giguère, V.; Saleh, M. Estrogen-related receptor alpha (ERR α) is a key regulator of intestinal homeostasis and protects against colitis. *Sci. Rep.* **2021**, *11*, 15073. [[CrossRef](#)]
79. Wilson, B.J.; Tremblay, A.M.; Deblois, G.; Sylvain-Drolet, G.; Giguère, V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. *Mol. Endocrinol.* **2010**, *24*, 1349–1358. [[CrossRef](#)]
80. Wisdom, R.; Johnson, R.S.; Moore, C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. *Embo. J.* **1999**, *18*, 188–197. [[CrossRef](#)]
81. Emmons, M.F.; Faiao-Flores, F.; Sharma, R.; Thapa, R.; Messina, J.L.; Becker, J.C.; Schadendorf, D.; Seto, E.; Sondak, V.K.; Koomen, J.M.; et al. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. *Cancer Res.* **2019**, *79*, 2947–2961. [[CrossRef](#)] [[PubMed](#)]
82. Gao, J.; Siddoway, B.; Huang, Q.; Xia, H. Inactivation of CREB mediated gene transcription by HDAC8 bound protein phosphatase. *Biochem. Biophys. Res. Commun.* **2009**, *379*, 1–5. [[CrossRef](#)] [[PubMed](#)]
83. Kaiser, F.J.; Ansari, M.; Braunholz, D.; Gil-Rodríguez, M.C.; Decroos, C.; Wilde, J.J.; Fincher, C.T.; Kaur, M.; Bando, M.; Amor, D.J.; et al. Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance. *Hum. Mol. Genet.* **2014**, *23*, 2888–2900. [[CrossRef](#)] [[PubMed](#)]
84. Mormino, A.; Coccozza, G.; Fontemaggi, G.; Valente, S.; Esposito, V.; Santoro, A.; Bernardini, G.; Santoni, A.; Fazi, F.; Mai, A.; et al. Histone-deacetylase 8 drives the immune response and the growth of glioma. *Glia* **2021**, *69*, 2682–2698. [[CrossRef](#)]
85. Spreafico, M.; Cafora, M.; Bragato, C.; Capitano, D.; Marasca, F.; Bodega, B.; De Palma, C.; Mora, M.; Gelfi, C.; Marozzi, A.; et al. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy. *Pharmacol. Res.* **2021**, *170*, 105750. [[CrossRef](#)]
86. Li, M.-L.; Su, X.-M.; Ren, Y.; Zhao, X.; Kong, L.-F.; Kang, J. HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization. *Respir. Res.* **2020**, *21*, 62. [[CrossRef](#)]
87. Lee, H.; Sengupta, N.; Villagra, A.; Rezai-Zadeh, N.; Seto, E. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. *Mol. Cell. Biol.* **2006**, *26*, 5259–5269. [[CrossRef](#)]
88. Waltregny, D.; Glenisson, W.; Tran, S.L.; North, B.J.; Verdin, E.; Colige, A.; Castronovo, V. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. *FASEB J.* **2005**, *19*, 966–968. [[CrossRef](#)]
89. Song, S.; Wang, Y.; Xu, P.; Yang, R.; Ma, Z.; Liang, S.; Zhang, G. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma. *Int. J. Oncol.* **2015**, *47*, 1819–1828. [[CrossRef](#)]
90. Ahn, M.Y.; Yoon, J.H. Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. *Oncol. Rep.* **2017**, *37*, 540–546. [[CrossRef](#)]
91. Moreno, D.A.; Scrideli, C.A.; Cortez, M.A.A.; De Paula Queiroz, R.; Valera, E.T.; Da Silva Silveira, V.; Yunes, J.A.; Brandalise, S.R.; Tone, L.G. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. *Br. J. Haematol.* **2010**, *150*, 665–673. [[CrossRef](#)] [[PubMed](#)]
92. Oehme, I.; Deubzer, H.E.; Wegener, D.; Pickert, D.; Linke, J.-P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S.M.; Von Deimling, A. Histone deacetylase 8 in neuroblastoma tumorigenesis. *Clin. Cancer Res.* **2009**, *15*, 91–99. [[CrossRef](#)] [[PubMed](#)]

93. Zhu, Y.J.; Xu, Q.; Shao, M.Y.; Cao, X.Y.; Wu, Z.R.; Chen, Y.W.; Bu, H.; Shi, Y.J. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma. *Hepatobiliary Pancreat. Dis. Int.* **2019**, *18*, 464–470. [[CrossRef](#)] [[PubMed](#)]
94. Tilekar, K.; Upadhyay, N.; Jänsch, N.; Schweipert, M.; Mrowka, P.; Meyer-Almes, F.J.; Ramaa, C.S. Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. *Bioorg. Chem.* **2020**, *95*, 103522. [[CrossRef](#)] [[PubMed](#)]
95. Mahajan, M.; Suryavanshi, S.; Bhowmick, S.; Alasmay, F.A.; Almutairi, T.M.; Islam, M.A.; Kaul-Ghanekar, R. Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity. *Biophys. Chem.* **2021**, *273*, 106588. [[CrossRef](#)] [[PubMed](#)]
96. Ramos, T.L.; Sánchez-Abarca, L.I.; Redondo, A.; Hernández-Hernández, Á.; Almeida, A.M.; Puig, N.; Rodríguez, C.; Ortega, R.; Preciado, S.; Rico, A.; et al. HDAC8 overexpression in mesenchymal stromal cells from JAK2⁺ myeloproliferative neoplasms: A new therapeutic target? *Oncotarget* **2017**, *8*, 28187–28202. [[CrossRef](#)]
97. Lopez, G.; Bill, K.L.; Bid, H.K.; Braggio, D.; Constantino, D.; Prudner, B.; Zewdu, A.; Batte, K.; Lev, D.; Pollock, R.E. HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). *PLoS ONE* **2015**, *10*, e0133302. [[CrossRef](#)] [[PubMed](#)]
98. Martínez-Pacheco, H.; Ramírez-Galicia, G.; Vergara-Arias, M.; Gertsch, J.; Fragoso-Vazquez, J.M.; Mendez-Luna, D.; Abujamra, A.L.; Cristina, C.L.; Cecilia, R.M.; Mendoza-Lujambio, I.; et al. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8. *Anti Cancer Agents Med. Chem.* **2017**, *17*, 927–940. [[CrossRef](#)]
99. Watters, J.M.; Wright, G.; Smith, M.A.; Shah, B.; Wright, K.L. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. *Biochem. Biophys. Res. Commun.* **2021**, *534*, 773–779. [[CrossRef](#)]
100. Kang, Y.; Nian, H.; Rajendran, P.; Kim, E.; Dashwood, W.; Pinto, J.; Boardman, L.; Thibodeau, S.; Limburg, P.; Löhr, C. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. *Cell Death Dis.* **2014**, *5*, e1476. [[CrossRef](#)]
101. Wang, Z.T.; Chen, Z.J.; Jiang, G.M.; Wu, Y.M.; Liu, T.; Yi, Y.M.; Zeng, J.; Du, J.; Wang, H.S. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. *Cell. Signal.* **2016**, *28*, 506–515. [[CrossRef](#)] [[PubMed](#)]
102. Yan, W.; Liu, S.; Xu, E.; Zhang, J.; Zhang, Y.; Chen, X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. *Oncogene* **2013**, *32*, 599–609. [[CrossRef](#)] [[PubMed](#)]
103. Singh, R.K.; Cho, K.; Padi, S.K.; Yu, J.; Haldar, M.; Mandal, T.; Yan, C.; Cook, G.; Guo, B.; Mallik, S.; et al. Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels. *J. Biol. Chem.* **2015**, *290*, 6607–6619. [[CrossRef](#)] [[PubMed](#)]
104. Park, S.Y.; Jun, J.A.; Jeong, K.J.; Heo, H.J.; Sohn, J.S.; Lee, H.Y.; Park, C.G.; Kang, J. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. *Oncol. Rep.* **2011**, *25*, 1677–1681. [[CrossRef](#)] [[PubMed](#)]
105. An, P.; Li, J.; Lu, L.; Wu, Y.; Ling, Y.; Du, J.; Chen, Z.; Wang, H. Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals. *Eur. J. Pharmacol.* **2019**, *845*, 16–23. [[CrossRef](#)] [[PubMed](#)]
106. Hsieh, C.L.; Ma, H.P.; Su, C.M.; Chang, Y.J.; Hung, W.Y.; Ho, Y.S.; Huang, W.J.; Lin, R.K. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. *Life Sci.* **2016**, *151*, 7–14. [[CrossRef](#)]
107. Shankar, E.; Pandey, M.; Verma, S.; Abbas, A.; Candamo, M.; Kanwal, R.; Shukla, S.; MacLennan, G.T.; Gupta, S. Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. *Mol. Carcinog.* **2020**, *59*, 955–966. [[CrossRef](#)]
108. Wang, Y.F.; Liu, F.; Sherwin, S.; Farrelly, M.; Yan, X.G.; Croft, A.; Liu, T.; Jin, L.; Zhang, X.D.; Jiang, C.C. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells. *J. Investig. Dermatol.* **2018**, *138*, 922–932. [[CrossRef](#)]
109. Tsai, C.Y.; Ko, H.J.; Chiou, S.J.; Lai, Y.L.; Hou, C.C.; Javaria, T.; Huang, Z.Y.; Cheng, T.S.; Hsu, T.I.; Chuang, J.Y.; et al. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β -Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. *Int. J. Mol. Sci.* **2021**, *22*, 5907. [[CrossRef](#)]
110. Zhao, G.; Wang, G.; Bai, H.; Li, T.; Gong, F.; Yang, H.; Wen, J.; Wang, W. Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137. *Eur. J. Pharmacol.* **2017**, *802*, 20–26. [[CrossRef](#)]
111. Wu, J.; Zhang, L.; Feng, Y.; Khadka, B.; Fang, Z.; Liu, J. HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8. *Biol. Chem.* **2021**, *402*, 461–468. [[CrossRef](#)] [[PubMed](#)]
112. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Franklin, R.A.; Montalto, G.; Cervello, M.; Libra, M.; Candido, S.; Malaponte, G.; et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. *Oncotarget* **2012**, *3*, 1068–1111. [[CrossRef](#)] [[PubMed](#)]
113. Ha, S.D.; Lewin, N.; Li, S.S.C.; Kim, S.O. HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells. *Cells* **2021**, *10*, 1101. [[CrossRef](#)] [[PubMed](#)]
114. Kindler, T.; Lipka, D.B.; Fischer, T. FLT3 as a therapeutic target in AML: Still challenging after all these years. *Blood* **2010**, *116*, 5089–5102. [[CrossRef](#)]
115. Yamauchi, Y.; Boukari, H.; Banerjee, I.; Sbalzarini, I.F.; Horvath, P.; Helenius, A. Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry. *PLoS Pathog.* **2011**, *7*, e1002316. [[CrossRef](#)]

116. Chelladurai, P.; Dabral, S.; Basineni, S.R.; Chen, C.N.; Schmoranzler, M.; Bender, N.; Feld, C.; Nötzold, R.R.; Dobрева, G.; Wilhelm, J.; et al. Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. *Sci. Rep.* **2020**, *10*, 12864. [[CrossRef](#)]
117. Wedel, T.; Van Eys, G.J.; Waltregny, D.; Glenisson, W.; Castronovo, V.; Vanderwinden, J.M. Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders. *Neurogastroenterol. Motil.* **2006**, *18*, 526–538. [[CrossRef](#)]
118. Long, K.; Vaughn, Z.; McDaniels, M.D.; Joyasawal, S.; Przepiorski, A.; Parasky, E.; Sander, V.; Close, D.; Johnston, P.A.; Davidson, A.J.; et al. Validation of HDAC8 Inhibitors as Drug Discovery Starting Points to Treat Acute Kidney Injury. *ACS Pharmacol. Transl. Sci.* **2022**, *5*, 207–215. [[CrossRef](#)]
119. Lin, F.L.; Yen, J.L.; Kuo, Y.C.; Kang, J.J.; Cheng, Y.W.; Huang, W.J.; Hsiao, G. HDAC8 Inhibitor WK2-16 Therapeutically Targets Lipopolysaccharide-Induced Mouse Model of Neuroinflammation and Microglial Activation. *Int. J. Mol. Sci.* **2019**, *20*, 410. [[CrossRef](#)]
120. Marek, M.; Kannan, S.; Hauser, A.-T.; Mourão, M.M.; Caby, S.; Cura, V.; Stolfa, D.A.; Schmidtkunz, K.; Lancelot, J.; Andrade, L. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke *Schistosoma mansoni*. *PLoS Pathog.* **2013**, *9*, e1003645. [[CrossRef](#)]
121. Vaca, H.R.; Celentano, A.M.; Macchiaroli, N.; Kamenetzky, L.; Camicia, F.; Rosenzvit, M.C. Histone deacetylase enzymes as potential drug targets of Neglected Tropical Diseases caused by cestodes. *PLoS Pathog.* **2019**, *9*, 120–132. [[CrossRef](#)]
122. Zhao, T.; Kee, H.J.; Bai, L.; Kim, M.K.; Kee, S.J.; Jeong, M.H. Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway. *Front. Pharmacol.* **2021**, *12*, 677757. [[CrossRef](#)]
123. Zhao, T.; Kee, H.J.; Kee, S.J.; Jeong, M.H. Hdac8 Inhibitor Alleviates Transverse Aortic Constriction-Induced Heart Failure in Mice by Downregulating Ace1. *Oxidative Med. Cell. Longev.* **2022**, *2022*, 6227330. [[CrossRef](#)]
124. Kee, H.J.; Ryu, Y.; Seok, Y.M.; Choi, S.Y.; Sun, S.; Kim, G.R.; Jeong, M.H. Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice. *Clin. Hypertens.* **2019**, *25*, 13. [[CrossRef](#)] [[PubMed](#)]
125. Saito, S.; Zhuang, Y.; Suzuki, T.; Ota, Y.; Bateman, M.E.; Alkhatib, A.L.; Morris, G.F.; Lasky, J.A. HDAC8 inhibition ameliorates pulmonary fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2019**, *316*, L175–L186. [[CrossRef](#)]
126. Lee, C.H.; Choi, Y.; Cho, H.; Bang, I.H.; Hao, L.; Lee, S.O.; Jeon, R.; Bae, E.J.; Park, B.H. Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis. *Biochem. Pharmacol.* **2021**, *183*, 114312. [[CrossRef](#)] [[PubMed](#)]
127. Kim, D.S.; Kwon, J.E.; Lee, S.H.; Kim, E.K.; Ryu, J.G.; Jung, K.A.; Choi, J.W.; Park, M.J.; Moon, Y.M.; Park, S.H.; et al. Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells. *Front. Immunol.* **2018**, *9*, 1525. [[CrossRef](#)]
128. Wang, P.; Mao, Z.; Pan, Q.; Lu, R.; Huang, X.; Shang, X.; Zhang, R.; You, H. Histone deacetylase-4 and histone deacetylase-8 regulate interleukin-1 β -induced cartilage catabolic degradation through MAPK/JNK and ERK pathways. *Int. J. Mol. Med.* **2018**, *41*, 2117–2127. [[CrossRef](#)]
129. Huang, W.J.; Wang, Y.C.; Chao, S.W.; Yang, C.Y.; Chen, L.C.; Lin, M.H.; Hou, W.C.; Chen, M.Y.; Lee, T.L.; Yang, P.; et al. Synthesis and biological evaluation of *ortho*-aryl *N*-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. *ChemMedChem* **2012**, *7*, 1815–1824. [[CrossRef](#)]
130. Spreafico, M.; Gruszka, A.M.; Valli, D.; Mazzola, M.; Deflorian, G.; Quinte, A.; Totaro, M.G.; Battaglia, C.; Alcalay, M.; Marozzi, A.; et al. HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia. *Front. Cell Dev. Biol.* **2020**, *8*, 844. [[CrossRef](#)]
131. Shen, J.; Najafi, S.; Ståble, S.; Fabian, J.; Koeneke, E.; Kolbinger, F.R.; Wrobel, J.K.; Meder, B.; Distel, M.; Heimbürg, T.; et al. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. *Cell Death Differ.* **2018**, *25*, 2053–2070. [[CrossRef](#)] [[PubMed](#)]
132. Zhang, P.; Brinton, L.T.; Williams, K.; Sher, S.; Orwick, S.; Tzung-Huei, L.; Mims, A.S.; Coss, C.C.; Kulp, S.K.; Youssef, Y.; et al. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. *Clin. Cancer Res.* **2021**, *27*, 2352–2366. [[CrossRef](#)]
133. Zhang, B.; Liu, B.; Chen, D.; Setroikromo, R.; Haisma, H.J.; Quax, W.J. Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. *Cancers* **2019**, *11*, 645. [[CrossRef](#)]
134. Krennhubec, K.; Marshall, B.L.; Hedglin, M.; Verdin, E.; Ulrich, S.M. Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2874–2878. [[CrossRef](#)] [[PubMed](#)]
135. Yang, Y.C.; Chen, C.N.; Wu, C.I.; Huang, W.J.; Kuo, T.Y.; Kuan, M.C.; Tsai, T.H.; Huang, J.S.; Huang, C.Y. NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. *Evid. Based Complement. Altern. Med.* **2013**, *2013*, 514908. [[CrossRef](#)]
136. Kampa-Schittenhelm, K.M.; Heinrich, M.C.; Akmut, F.; Dohner, H.; Dohner, K.; Schittenhelm, M.M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol. Cancer* **2013**, *12*, 19. [[CrossRef](#)]
137. Halder, A.K.; Mallick, S.; Shikha, D.; Saha, A.; Saha, K.D.; Jha, T. Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity. *RSC Adv.* **2015**, *5*, 72373–72386. [[CrossRef](#)]
138. Amin, S.A.; Adhikari, N.; Jha, T. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? *Pharmacol. Res.* **2017**, *122*, 8–19. [[CrossRef](#)]

139. Cheng, X.C.; Wang, R.L.; Dong, Z.K.; Li, J.; Li, Y.Y.; Li, R.R. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold. *Bioorg. Med. Chem.* **2012**, *20*, 5738–5744. [[CrossRef](#)] [[PubMed](#)]
140. Banerjee, S.; Adhikari, N.; Amin, S.A.; Jha, T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. *Eur. J. Med. Chem.* **2019**, *164*, 214–240. [[CrossRef](#)] [[PubMed](#)]
141. Chotitumnavee, J.; Yamashita, Y.; Takahashi, Y.; Takada, Y.; Iida, T.; Oba, M.; Itoh, Y.; Suzuki, T. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). *Chem. Commun.* **2022**, *58*, 4635–4638. [[CrossRef](#)]
142. Sun, Z.; Deng, B.; Yang, Z.; Mai, R.; Huang, J.; Ma, Z.; Chen, T.; Chen, J. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. *Eur. J. Med. Chem.* **2022**, *239*, 114544. [[CrossRef](#)]
143. Ferrari, L.; Bragato, C.; Brioschi, L.; Spreafico, M.; Esposito, S.; Pezzotta, A.; Pizzetti, F.; Moreno-Fortuny, A.; Bellipanni, G.; Giordano, A.; et al. HDAC8 regulates canonical Wnt pathway to promote differentiation in skeletal muscles. *J. Cell. Physiol.* **2019**, *234*, 6067–6076. [[CrossRef](#)] [[PubMed](#)]
144. Katayama, S.; Morii, A.; Makanga, J.O.; Suzuki, T.; Miyata, N.; Inazu, T. HDAC8 regulates neural differentiation through embryoid body formation in P19 cells. *Biochem. Biophys. Res. Commun.* **2018**, *498*, 45–51. [[CrossRef](#)]
145. Morii, A.; Katayama, S.; Inazu, T. Establishment of a Simple Method for Inducing Neuronal Differentiation of P19 EC Cells without Embryoid Body Formation and Analysis of the Role of Histone Deacetylase 8 Activity in This Differentiation. *Biol. Pharm. Bull.* **2020**, *43*, 1096–1103. [[CrossRef](#)]
146. Hua, W.K.; Qi, J.; Cai, Q.; Carnahan, E.; Ramirez, M.A.; Li, L.; Marcucci, G.; Kuo, Y.H. HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. *Blood* **2017**, *130*, 2619–2630. [[CrossRef](#)]